Receipt of nasdaq delisting determination - plans to appeal

August 30, 2024 biodexa pharmaceuticals plc (“biodexa” or the “company”) receipt of nasdaq delisting determination plans to appeal biodexa pharmaceuticals plc (nasdaq: bdrx), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that on august 27, 2024, it received a staff determination letter (the “letter”) from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) notifying the company of the staff's determination to delist the company's securities from the nasdaq capital market because the company's securities have had a closing bid price below $1.00 for 30 consecutive business days, which triggers a notice of delisting pursuant to nasdaq listing rule 5550(a)(2) (the “rule”). normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the rule.
BDRX Ratings Summary
BDRX Quant Ranking